1- Tang Y-W, Sussman M, Liu D, Poxton IR, Schwartzman JD. Chapter 1- Molecular Medical Microbiology – The Expanding Concept. In: Tang Y-W, Sussman M, Liu D, Poxton I, Schwartzman J, editors. Molecular Medical Microbiology (Second Edition). Boston: Academic Press. 2015: 1-4.
2- Moradali MF, Ghods S, Rehm BHA. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Frontiers in Cellular and Infection Microbiology. 2017;7.
3- Jones P, Palser S, Pravle A, Hurley M, Smyth A. WS20. 1 Secular trends in Pseudomonas aeruginosa acquisition in the United Kingdom: a registry study. Journal of Cystic Fibrosis. 2016;1(15): S31.
4- van Duin D, Bonomo RA. Ceftazidime /Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016; 63(2): 234-41.
5- Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infect Dis. 2018; 5(11): 280.
6- Kong K-F, Jayawardena SR, del Puerto A, Wiehlmann L, Laabs U, Tümmler B, et al. Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. Gene. 2005; 358: 82-92.
7- Tawfik AF, Shibl AM, Aljohi MA, Altammami MA, Al-Agamy MH. Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates. Burns. 2012; 38(6): 855-60.
8- Ortiz de la Rosa JM, Nordmann P, Poirel L. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. 2019; 74(7): 1934-9.
9- Shiri Y, Karimiyan Ma. Reconstitution of Gene Network on Penicillin Resistance in E.coli Using Databases Information. New Findings in Veterinary Microbiology. 2020; 2(2): 1-9.
10- Patterson J, Tsilimigras M, Livesay D, Jacobs D. Evolution of Stability/Flexibility Relationships in Beta-Lactamase. Biophysical Journal. 2019; 116: 472.
11- Subedi D, Vijay AK, Willcox M. Overview of mechanisms of antibiotic resistance in Pseudomonas aeruginosa: an ocular perspective. Clin Exp Optom. 2018; 101(2): 162-71.
12- Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2017; 61(7).
13- Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014; 58(6): 3091-9.
14- MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation. Antimicrob Agents Chemother. 2017; 61(12).
15- Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, et al. UniProt: the Universal Protein knowledgebase. Nucleic acids research. 2004; 32(Database issue): 115-9.
16- Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic acids research. 2017; 45(Database issue): D362-D8.
17- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003; 13(11): 2498-504.
18- Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008; 24(2): 282-4.
19- Shiri Y, Solouki M, Ebrahimie E, Emamjomeh A, Zahiri J. Gibberellin causes wide transcriptional modifications in the early stage of grape cluster development. Genomics. 2019.
20- Shiri Y, Solouki M, Ebrahimie E, Emamjomeh A, Zahiri J. Unraveling the Transcriptional Complexity of Compactness in Sistan Grape Cluster. Plant Science. 2018.
21- Jiao X, Sherman BT, Huang DW, Stephens R, Baseler MW, Lane HC, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics (Oxford, England). 2012; 28(13): 1805-6.
22- Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995; 57(1): 289-300.
23- Li W, Yao Z, Zhang X, Huang F, Lin W, Lin X. Global protein expression profile response of planktonic Aeromonas hydrophila exposed to chlortetracycline. World Journal of Microbiology and Biotechnology. 2017; 33(4): 68.
24- Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009; 22(1): 161-82, Table of Contents.
25- Torrens G, Hernández SB, Ayala JA, Moya B, Juan C, Cava F, et al. Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling. mSystems. 2019; 4(6).
26- Irazoki O, Hernandez SB, Cava F. Peptidoglycan Muropeptides: Release, Perception, and Functions as Signaling Molecules. Frontiers in Microbiology. 2019; 10.
27- Juan C, Torrens G, González-Nicolau M, Oliver A. Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiol Rev. 2017; 41(6): 781-815.
28- Vermassen A, Leroy S, Talon R, Provot C, Popowska M, Desvaux M. Cell Wall Hydrolases in Bacteria: Insight on the Diversity of Cell Wall Amidases, Glycosidases and Peptidases Toward Peptidoglycan. Front Microbiol. 2019; 10: 331.
29- Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, et al. NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(9): 3557-63.
30- Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, et al. Catalytic spectrum of the penicillin-binding protein 4 of Pseudomonas aeruginosa, a nexus for the induction of β-lactam antibiotic resistance. J Am Chem Soc. 2015; 137(1): 190-200.
31- Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582-610.
32- Dik DA, Fisher JF, Mobashery S. Cell-Wall Recycling of the Gram-Negative Bacteria and the Nexus to Antibiotic Resistance. Chem Rev. 2018; 118(12): 5952-84.
33- Fisher JF, Mobashery S. The sentinel role of peptidoglycan recycling in the β-lactam resistance of the Gram-negative Enterobacteriaceae and Pseudomonas aeruginosa. Bioorg Chem. 2014; 56: 41-8.
34- López-Causapé C, Cabot G, Del Barrio-Tofiño E, Oliver A. The Versatile Mutational Resistome of Pseudomonas aeruginosa. Front Microbiol. 2018; 9: 685.
35- Zincke D, Balasubramanian D, Silver LL, Mathee K. Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother. 2016; 60(2): 936-45.
36- Schneider I, Queenan AM, Bauernfeind A. Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa. Antimicrob Agents Chemother. 2006; 50(4): 1330-5.